Commonwealth Equity Services LLC raised its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 52.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 5,476 shares of the medical equipment provider’s stock after purchasing an additional 1,881 shares during the quarter. Commonwealth Equity Services LLC’s holdings in ABIOMED were worth $1,779,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in ABMD. AQR Capital Management LLC increased its position in ABIOMED by 193.5% during the 3rd quarter. AQR Capital Management LLC now owns 1,207,996 shares of the medical equipment provider’s stock valued at $543,297,000 after purchasing an additional 796,482 shares during the period. BlackRock Inc. increased its position in ABIOMED by 10.3% during the 3rd quarter. BlackRock Inc. now owns 3,117,569 shares of the medical equipment provider’s stock valued at $1,402,127,000 after purchasing an additional 290,298 shares during the period. Vanguard Group Inc increased its position in ABIOMED by 5.9% during the 3rd quarter. Vanguard Group Inc now owns 4,647,227 shares of the medical equipment provider’s stock valued at $2,090,091,000 after purchasing an additional 260,829 shares during the period. Vanguard Group Inc. increased its position in ABIOMED by 5.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,647,227 shares of the medical equipment provider’s stock valued at $2,090,091,000 after purchasing an additional 260,829 shares during the period. Finally, Janus Henderson Group PLC increased its position in ABIOMED by 90.1% during the 3rd quarter. Janus Henderson Group PLC now owns 517,612 shares of the medical equipment provider’s stock valued at $232,797,000 after purchasing an additional 245,286 shares during the period. 86.96% of the stock is owned by institutional investors and hedge funds.

In other ABIOMED news, Director Martin P. Sutter sold 20,000 shares of the stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $360.16, for a total transaction of $7,203,200.00. Following the transaction, the director now directly owns 195,491 shares in the company, valued at approximately $70,408,038.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Martin P. Sutter sold 19,943 shares of the stock in a transaction on Monday, February 4th. The stock was sold at an average price of $350.28, for a total value of $6,985,634.04. Following the completion of the transaction, the director now owns 212,943 shares in the company, valued at $74,589,674.04. The disclosure for this sale can be found here. Insiders have sold a total of 74,928 shares of company stock worth $26,515,812 over the last 90 days. Company insiders own 3.50% of the company’s stock.

ABIOMED stock opened at $325.61 on Friday. The company has a market cap of $14.66 billion, a price-to-earnings ratio of 132.90, a price-to-earnings-growth ratio of 3.27 and a beta of 0.37. ABIOMED, Inc. has a 52-week low of $274.02 and a 52-week high of $459.75.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, January 31st. The medical equipment provider reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.03. The firm had revenue of $200.56 million for the quarter, compared to analysts’ expectations of $200.60 million. ABIOMED had a return on equity of 20.31% and a net margin of 30.12%. On average, sell-side analysts anticipate that ABIOMED, Inc. will post 3.58 earnings per share for the current fiscal year.

A number of analysts have weighed in on ABMD shares. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $370.00 target price for the company in a research report on Friday, January 18th. ValuEngine cut ABIOMED from a “buy” rating to a “hold” rating in a report on Tuesday, November 20th. Morgan Stanley cut their price target on ABIOMED from $496.00 to $461.00 and set an “overweight” rating on the stock in a report on Wednesday, January 2nd. Finally, BidaskClub cut ABIOMED from a “buy” rating to a “hold” rating in a report on Wednesday, January 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. ABIOMED has a consensus rating of “Buy” and a consensus price target of $421.00.

TRADEMARK VIOLATION NOTICE: This piece was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://theolympiareport.com/2019/03/15/abiomed-inc-abmd-holdings-increased-by-commonwealth-equity-services-llc.html.

ABIOMED Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Further Reading: What is a Leveraged Buyout (LBO)?

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.